Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue EstimatesDare Bioscience (DARE) delivered earnings and revenue surprises of +39.39% and +1,775.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?